Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:India
|
| gptkbp:ATCCode |
C10BX14
|
| gptkbp:brand |
gptkb:Lipaglyn
|
| gptkbp:CASNumber |
1018899-04-1
|
| gptkbp:chemicalFormula |
C25H27NO4S
|
| gptkbp:developedBy |
gptkb:Zydus_Cadila
|
| gptkbp:eliminationHalfLife |
5.6 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Saroglitazar
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PPAR alpha agonist
PPAR gamma agonist |
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
437.6 g/mol
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
edema
weight gain increased liver enzymes |
| gptkbp:usedFor |
treatment of diabetic dyslipidemia
treatment of hypertriglyceridemia treatment of non-alcoholic fatty liver disease treatment of non-alcoholic steatohepatitis |
| gptkbp:bfsParent |
gptkb:Zydus_Cadila
|
| gptkbp:bfsLayer |
6
|